NEW YORK (GenomeWeb News) – Rosetta Genomics today announced a deal with Precision Therapeutics to co-market Rosetta's miRview mets2 assay.

Under the terms of the agreement, the two firms will co-market in the US through July 30, 2014 the microRNA-based assay for the identification of the tumor of origin in cancers of unknown or uncertain primary (CUP). The deal includes certain pre-specified performance milestones.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Even when given the option, not too many authors choose double-blinded peer-review for their manuscripts, ScienceInsider reports.

In PNAS this week: transcriptional read-through in stressed cells, genome stability role for the epigenetic regulator CTCF, and more.

The Save the Redwoods League is teaming with researchers to sequence the genomes of the coast redwood and giant sequoia.

Two researchers have found that behavioral genetic defenses in criminal cases don't tend to affect outcomes, according to Popular Science.